Home › Calculator › UCBJF Dividend Calculator 2026
UCBJF Dividend DRIP Calculator 2026
0.60% YieldHealthcareUCB S.A. · OTC
Price: $282.93 · Annual div: $1.70/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When UCBJF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your UCBJF snowball 📈
$10,000 in UCBJF → $390.8K in 10 years · $15.40/month
About UCB S.A. (UCBJF) — Dividend Analysis 2026
UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam, a specialized nasal spray for acute rescue treatment of seizure clusters. Neupro is available for patients with Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Additionally, the company offers Evenity to treat osteoporosis in postmenopausal women, and BIMZELX, approved for conditions like psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also part of its offerings for systemic lupus erythematosus. In its robust development pipeline, UCB is advancing several investigational medicines, including rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged stereotypical seizures; Bepranemab targeting Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its core pharmaceutical activities, UCB also provides contract manufacturing services. The company has forged strategic collaboration agreements with major industry players such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. With its headquarters in Brussels, Belgium, and established in 1925, UCB maintains a significant international presence, operating across the United States, Japan, Germany, China, Belgium, and other key European markets including France, Italy, Spain, the United Kingdom, and Ireland.
Compare UCBJF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full UCBJF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open UCBJF position with:
🌍 UCBJF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold UCBJF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.60% | -2.20% | $60 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.51% | -2.29% | $51 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.48% | -2.32% | $48 / yr |
| 🇬🇧 UK ISA | 0% | 0.60% | -2.20% | $60 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.55% | -2.25% | $55 / yr |
| 🇨🇦 TFSA | 0% | 0.60% | -2.20% | $60 / yr |
| 🇨🇦 CA Taxable | 25% | 0.45% | -2.35% | $45 / yr |
| 🇦🇺 Super (pension) | 15% | 0.51% | -2.29% | $51 / yr |
| 🇦🇺 AU Taxable | 30% | 0.42% | -2.38% | $42 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.44% | -2.36% | $44 / yr |
| 🇫🇷 FR Taxable | 30% | 0.42% | -2.38% | $42 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 UCBJF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $1.70/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 UCBJF Dividend Payment Schedule
UCBJF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 UCBJF vs Healthcare Benchmarks
How UCBJF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for UCBJF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ UCBJF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the UCBJF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
UCB S.A. (UCBJF) is currently trading at $282.93, 12% below its 52-week high. The current dividend yield is 0.60% based on an annual payout of $1.70 per share.
UCBJF (UCB S.A.) — 0.60% Dividend Yield Analysis
UCB S.A. (UCBJF) is a healthcare stock currently trading at $282.93 with a dividend yield of 0.60%. The company pays an annual dividend of $1.70 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, UCBJF has grown its dividend at a compound annual rate of 11.7%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.